Table 1.

177Lu-PSMA-617.

Lu-177-PSMA-617	Information
Pharmacokinetics
Radiation Emission	Lu-177 emits radiation in a wavelength between 1–10 millimeters with energy of 479keV.
Cell Internalization	Lu-177 is internalized by cells after binding with PSMA-617 ligand.
Cell Penetration Range	PSMA-617 reaches short cell penetration range up to 670 µm.
Ionizing Radiation	Lu-177-PSMA-617 generates ionizing radiation, affecting mainly PC cells.
Half-Life	Lutetium has a seven-day half-life for optimal therapeutic effect.
Effective Radiation	96.3 keV beta radiation emission requires binding with ≥1mm tissue volume.
Micro Metastases	Ineffective for micro metastases (<1.2–3.0 millimeters).
Cinical Trial
VISION Study	Phase III study: Extended rPFS and OS compared to SOC for mCRPC patients.
TheraP Study	Phase II study: Higher therapeutic effect frequency with 177LuPSMA-617.
German Nuclear Medicine Study	Significant PSA reduction, increased QoL observed with 177LuPSMA-617.
LuPSMA Study	Phase II study: Therapeutic efficacy in PSA reduction, regression of metastatic changes.
OS Rate	Various studies show extended OS post 177Lu treatment.
Recurrence	Recurrence median after 177Lu treatment varies based on therapeutic effect.
Toxicity
Xerostomia	Common side effect: Dry mouth (xerostomia) due to accumulation in salivary glands.
Hematotoxicity	Common side effects include thrombocytopenia, anemia, and neutropenia.
Gastroenteritis Disorders	Nausea, vomiting, and gastrointestinal disorders post-treatment.
Fatigue	Common side effect reported by patients.
Nephrotoxicity	Presence in kidney tubules leads to nephrotoxicity.